Enliven Therapeutics (ELVN) logo

Enliven Therapeutics (ELVN) stock

Small molecule therapeutics , market cap $3.4B

$46.53
+0.26%

Quality Score
2
Below Average
In its industry
#74of 273
Checks firing
2of 14
Transition
From 52-week high
-25.3%
under its best in a year

ELVN's Quality Score was unchanged on Fri, Nov 20, at 2.

Follow ELVN's trial news. Pro members can get an alert when Enliven Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ELVN files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“prepare to initiate our pivotal Phase 3 trial of relcobatinib before year-end and plan for commercialization.”Trial start · SEC filing · Oct 14

Why is ELVN up?

Up 10% on Nov 6, and still 4% over its Nov 5 close.

  • It reported a diluted loss of $0.36 a share after the close on Nov 5.

Sources: Price history, Nov 6, 2026; SEC filing, Nov 5, 2026; Company release (8-K), Nov 5, 2026

1 more reason, free with an account →See every reason on ELVN →The other side, the timeline, and its peers, for Pro members.

Key facts on ELVN

Key facts on ELVN
Holding it back25.6% more shares than a year ago
Latest filing10-Q, Nov 5 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

ELVN in the news

Fri Nov 6Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update SEC filing 4:10 PM ET · PR Newswire and 2 more ELVN closed +10.4% that day.

Outlet counts from the GDELT Project.

ELVN catalysts

Coming up

After its last 4 reports it closed +4.2% on average, higher 4 of 4 times.

3 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for ELVN, and how long its cash lasts

Next step the company has named

End of 2026“prepare to initiate our pivotal Phase 3 trial of relcobatinib before year-end and plan for commercialization.”Trial start · SEC filing · Oct 14

What it means: when a trial begins, or reaches the stage the company named.

Lead program
Relcobatinib
Another trial
ENABLE-2Phase 3 · Recruiting · 450 people · main data estimated Dec 31, 2028 · NCT07905183

4 more trials, 1 more milestone and 27 filings, for Pro members.

Cash runway

The company says its cash lasts into 2030 (8-K, Nov 5).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Aug 13, 2025)
  • At-the-market share sales program (S-3ASR, filed Aug 13, 2025)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Chief Medical Officer Helen Louise Collins sold 5,000 shares on Nov 17, under a planned sale. 28 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Richard Fair’s 8 filings and quotes.

Get an alert when ELVN files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why ELVN scores 2

Below Averagefor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

  • +2Chart checks 2 of 14 firing right now, one point each
  • +2Long-term trend above a rising 200-⁠day average
  • Run-up adds
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Growth, Volatility, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on ELVN and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:39 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when ELVN's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How ELVN ranks in Biotech

ELVN is #74 of 273 by Quality Score.

How ELVN ranks in Biotech
RankStockQuality Score
74Enliven Therapeutics (ELVN) logoELVNEnliven Therapeutics2

Share count against a year before: ELVN +26%, SLS +87%, EWTX +3.2%, MBX +42%.

More in Biotech

When does ELVN report earnings, and what happens after?

Expected to report Tue Mar 2, after the close (in 101 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ELVN reported on Nov 5, 2026

The quarter

A loss of $0.36 a share, from $0.32.

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

ELVN's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “Strong balance sheet with $884 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into 2030”

From its results filing (SEC filing · Nov 5)

The numbers

Market value
$3.4B
today
Free cash flow
-$66.4M
last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ELVN: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+4.3%+1.1%+0.9%+10.4%
Mar 3May 7Aug 5Nov 5
ReportedGapReaction5
days
Nov 5, 2026After close+3.1%+10.4%+7.9%
Aug 5, 2026After close-0.6%+0.9%-3.0%
May 7, 2026After close+3.1%+1.1%+6.9%
Mar 3, 2026After close-0.6%+4.3%+5.2%

ELVN closed higher after 4 of its last 4 reports.

ELVN has 2 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on ELVN, and all 14 on every stock.Get in free →See the top 3 →Start Pro

ELVN RSI on Nov 20: 50.4, above its 50-day and 200-day averages

Not scored

RSI 50.4, MACD below signal, above both averages. Not scored.

The deep dive on ELVN

6 more findings on ELVN, each with its source, for Pro members.

ELVN share count over time

Shares: 25.6% more than a year ago (to Sep 30).

Shares of ELVN outstanding, as filed
Shares
outstanding
As
of
73.6MOct 28, 2026
73.3MJul 28, 2026
60.9MApr 28, 2026
59.8MFeb 19, 2026
Offerings, shelves, and splits of ELVN, from its filings
From its
filings
Filed
Raised $335M in a sale of shares, about 10% of its market valueJun 12, 2026
Registered shares for a later sale (S-3ASR)Aug 13, 2025
Raised $165M in a sale of shares, about 5% of its market valueJun 16, 2025
Registered shares for a later sale (S-3)Apr 18, 2024

ELVN insider trades

2 insiders sold $52.3M across 7 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellJ. Scott Garland$607KDirectorat $46.67 on Oct 1, filed Oct 5

All 7 insider filings on ELVN from the last six months, for Pro members.

ELVN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold ELVN?

In ETFs: ELVN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Enliven Therapeutics

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

65 employeesBurlingame, CAenliventherapeutics.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ELVN and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn ELVN's score around: 6 things
  • 6 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayOct 5J. Scott Garland sold ELVN$607K at $46.67, filed Oct 5

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: ELVN's Quality Score is 2 (Below Average), #74 of 273 in Biotech. Insiders sold $52.3M in the last 6 months (Form 4).

What does ELVN's Quality Score say?

ELVN scores 2 today, which Breakaway calls Below Average. It is #74 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 10% on Nov 6, and still 4% over its Nov 5 close. Shares: 25.6% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ELVN's Quality Score?

ELVN scores 2 today, which Breakaway calls Below Average (0 to 5). That is #74 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ELVN's 2.

Are insiders buying ELVN?

2 insiders sold $52.3M across 7 filings in the last 6 months. No open-⁠market buys on record. The newest is J. Scott Garland, Director, who sold $607K on Oct 1. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Enliven Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.